

Next-Generation Medical Devices

Semprus BioSciences' mission is to establish a new standard-of-care by significantly reducing serious health complications associated with medical devices, improving patient outcomes and contributing to health care cost efficiencies.

Company Overview

- **Semprus BioSciences** is a Cambridge, Mass.-based biomedical company that develops products designed to address the 56,000 annual deaths and \$11.2 billion in infection and thrombus complication costs¹ from vascular access products.

Opportunity

- Semprus is developing next-generation medical devices with anti-fouling modifications that are designed to provide the benefits of reducing complications such as microbial adhesion and thrombus over long durations
- **Semprus Sustain™ Technology**
 - Semprus' core technology that signifies a breakthrough for medical devices:
 - First non-leaching single surface modification that simultaneously reduces bacterial attachment and thrombus on medical devices for multiple months
 - Non-leaching technology does not require elution from the device to achieve its anti-fouling effect
 - Technology remains functional over extended periods of time
- Semprus is also developing new products with the potential to deliver drugs, bind with agents in the bloodstream to promote site-specific healing, or provide improved accuracy for diagnostics

Funding

2010

- In December, Semprus completed an \$18 million Series B financing round co-led by **SR One**, the corporate venture capital arm of GlaxoSmithKline, and **Foundation Medical Partners** (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic

2008

- In December, Semprus completed an \$8 million Series A financing round co-led by **SAM Ventures**, a venture capital firm focused on building next-generation life science companies, and **Pangaea Ventures**, a venture capital firm that invests in advanced materials, energy, biomedical, and environmental technology companies
- Since 2008, Semprus has received \$2.5 million in government funding from the **U.S. Department of Defense**, **Department of Energy**, the **National Institutes of Health** (NIH), and the **National Science Foundation** (NSF)

Business Strategy

- Semprus is in the process of negotiating partnerships with leading, publicly traded medical device firms while developing its own proprietary products for clinical trials and commercialization
- Semprus is discussing other partnerships with medical, chemical and diversified technology conglomerates, where our broad platform can provide significant differentiation and value to their product portfolios
- Semprus has worldwide licenses secured from the Massachusetts Institute of Technology and the University of Washington, and hold numerous proprietary intellectual property filings
- Semprus' laboratory and office complex is located in Kendall Square and employs 27 full-time professionals
- For more information, visit us at <http://www.semprusbio.com>

Delivering paradigm-shifting technologies to improve patient outcomes and reduce complications associated with medical devices

¹ *Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.*